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Autonomous feedback loop of 
RUNX1-p53-CBFB in acute myeloid 
leukemia cells
Ken Morita1, Mina Noura1, Chieko Tokushige1, Shintaro Maeda1, Hiroki Kiyose1, Gengo 
Kashiwazaki2, Junichi Taniguchi2, Toshikazu Bando2, Kenichi Yoshida3, Toshifumi Ozaki4, 
Hidemasa Matsuo1, Seishi Ogawa3, Pu Paul Liu5, Tatsutoshi Nakahata6, Hiroshi Sugiyama2, 
Souichi Adachi1,7 & Yasuhiko Kamikubo1
Although runt-related transcription factor 1 (RUNX1) and its associating core binding factor-β (CBFB) 
play pivotal roles in leukemogenesis, and inhibition of RUNX1 has now been widely recognized as 
a novel strategy for anti-leukemic therapies, it has been elusive how leukemic cells could acquire 
the serious resistance against RUNX1-inhibition therapies and also whether CBFB could participate 
in this process. Here, we show evidence that p53 (TP53) and CBFB are sequentially up-regulated in 
response to RUNX1 depletion, and their mutual interaction causes the physiological resistance against 
chemotherapy for acute myeloid leukemia (AML) cells. Mechanistically, p53 induced by RUNX1 gene 
silencing directly binds to CBFB promoter and stimulates its transcription as well as its translation, 
which in turn acts as a platform for the stabilization of RUNX1, thereby creating a compensative 
RUNX1-p53-CBFB feedback loop. Indeed, AML cells derived from relapsed cases exhibited higher CBFB 
expression levels compared to those from primary AML cells at diagnosis, and these CBFB expressions 
were positively correlated to those of p53. Our present results underscore the importance of RUNX1-
p53-CBFB regulatory loop in the development and/or maintenance of AML cells, which could be 
targeted at any sides of this triangle in strategizing anti-leukemia therapies.
CBFB is the beta subunit of heterodimeric core-binding transcription factor which master-regulates vital sub-
sets of genes implicated in hematopoiesis and osteogenesis1. This beta subunit which lacks DNA-binding capa-
bility, facilitates the association of DNA-binding runt domain in alpha subunit with its target DNA sequences 
(5′-TGTGGT-3′ and much rarely 5′-TGCGGT-3′) in various gene promoters as well as enhancers2. The alpha sub-
unit is constituted of three representative members; RUNX1, RUNX2 and RUNX3. Although each of RUNX fam-
ily members plays distinct physiological roles in vivo, their functions are consistently redundant in malignant cells 
and thus could be targeted simultaneously for anti-tumor strategies3,4. We have recently reported that anti-tumor 
potential of RUNX inhibition is primarily mediated by pro-apoptotic p53-dependent cell death pathway5. Based 
on our results, RUNX inhibition led to the transcriptional down-regulation of genes involved in the prohibition of 
p53 such as BCL11A and TRIM24, resulting in up-regulation of p53-mediated pro-apoptotic signaling in tumor 
cells. In addition, we have also demonstrated that the intracellular amount of CBFB which is equivalent to that 
of total RUNX (RUNX1 + RUNX2 + RUNX3), is consistently higher in malignant tissues relative to their corre-
sponding normal ones, suggesting that CBFB is one of the ideal targets for anti-cancer therapies5.
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Tumor suppressor p53, a distant relative of RUNX family6, is widely known as a nuclear transcription fac-
tor that regulates the expression of stress response genes and mediates a variety of anti-proliferative processes 
through transactivating its downstream target genes implicated in cell cycle checkpoints, DNA damage/repair 
and apoptosis7. The p53-resposive element has been extensively studied and the most reliable sequences are cur-
rently characterized as 10-nucleotide half-sites of RRRCWWGYYY-N-RRRCWWGYYY (R = purine, Y = pyrim-
idine, W = A/T and N = 0 to 13-nucleotide spacer)8. Of note, the emerging evidence indicates that the potential 
p53-target sites are not always restricted to the above-mentioned original decamer half-sites, and DNA sequences 
with several nucleotide mismatches seems acceptable and functional9–11, implying that number of p53-target 
genes might be much greater than that previously estimated. Consistent with its extreme importance as an onco-
suppressor, somatic mutations of p53 gene have been considered to be one of the most frequent alterations in 
human cancers, and most mutations are single-base substitutions found within the genomic region encoding 
its sequence-specific DNA-binding domain12,13. In a sharp contrast to wild-type p53 with the extremely short 
half-life, mutated p53 acquires oncogenic gain-of-function properties with the extended half-life and acts as a 
dominant-negative inhibitor against wild-type p5314,15. Since p53 mutations are detectable primarily within its 
central DNA-binding domain, it is highly likely that mutant p53 lacks sequence-specific transactivation ability or 
acquires a capability to induce certain set of its target genes distinct from that of wild-type p5313.
In contrast to the majority of tumors, it has been described that p53 is infrequently mutated in overall de novo 
AML cases (less than 10%)16. It is worth noting, however, that its mutation rate elevates strikingly in complex 
karyotype de novo AML cases17,18 or therapy-related AML cases and they display a poor prognosis19. Wong TN et 
al. have recently described that p53 mutations arise during the quite early phase of the disease progression prior 
to any chemotherapeutic treatments, indicating the importance of its mutations in the initiation and propaga-
tion of AML20. Additionally, it has been shown that p53 mutations are strongly associated with transformation 
of AML in patients into myeloproliferative neoplasms, suggesting their vital involvement during the leukemic 
transformations21.
In spite of these findings, neither the precise molecular mechanisms behind the transcriptional regulation 
of CBFB nor the functional/physical association between CBFB and p53 has so far remained entirely elusive. 
Furthermore, the actual molecular basis of how AML cells could adapt to RUNX1-attenuated environment has 
been largely unknown. Here, we have sought to clarify the transcriptional regulatory mechanisms of CBFB and 
also examined the presence of the cell-autonomous compensation mechanisms after RUNX1-inhibition therapy 
in AML cells.
Results
p53 transcriptionally regulates CBFB expression. To investigate RUNX1 depletion-mediated cellular 
responses, we have constructed tetracycline-inducible shRNAs targeting RUNX1 (sh_RUNX1 #1 and #2) and 
lentivirally-transduced them into AML-derived MV4-11 cells. As shown in Fig. 1a, RUNX1 gene silencing sig-
nificantly induced wild-type p53 expression in MV4-11 cells as described previously5. We have also found that, 
like p53, CBFB expression is increased upon RUNX1-knockdown. The total amount of RUNX family members 
(RUNX1 + RUNX2 + RUNX3), which was estimated by RT-qPCR with primer set specifically amplifying the 
common coding sequence of all RUNX family members, was decreased in these RUNX1-knocked down AML 
cells (Supplementary Fig. S1a). In addition, the simultaneous knockdown of RUNX1 plus RUNX2 and/or RUNX3 
further stimulated CBFB expression as compared to that in the absence of RUNX1 alone. We also found that these 
CBFB up-regulations are proportional to the extent of p53 induction in these cells (Supplementary Fig. S1b).
Previously, Berardi MJ, Warren AJ and Yan J et al. reported that RUNX family members and CBFB form a het-
erodimeric complex and this complex formation stabilizes RUNX1/CBFB complex on its target DNA6,22,23, raising 
a possibility that depletion of RUNX1 might disrupt the stable RUNX1/CBFB complex and then destabilize CBFB. 
Contrary to this hypothesis, our present results clearly showed that the amount of CBFB is remarkably increased 
upon RUNX knockdown under our experimental conditions, indicating that the above-mentioned previous 
hypothesis is not the case. Considering that the anti-tumor potency of RUNX gene silencing is highly dependent 
on functional p53 with the sequence-specific transactivation capability, we have sought to examine a possible 
involvement of p53 in the transcriptional regulation of CBFB. Close inspection of the gene expression profiles in 
de novo AML patients from two independent studies revealed the presence of the positive correlation between 
the expression levels of p53 and CBFB (Fig. 1b). In a good agreement with these observations, knockdown of 
p53 in MV4-11 cells caused an obvious reduction in CBFB as well as RUNX1 relative to non-silencing control 
cells both at the mRNA and protein levels (Fig. 1c, Supplementary Fig. S2a). When MV4-11 cells were exposed 
to p53 inducer Nutlin-324, CBFB level was up-regulated in a dose-dependent manner (Fig. 1d). In addition, the 
expression level of RUNX1 was reduced in CBFB-knocked down MV4-11 cells, whereas p53 was induced in 
response to CBFB depletion (Fig. 1e). To further confirm these results, CBFB was overexpressed in MV4-11 
cells. As expected, forced expression of CBFB resulted in a significant increase and decrease in RUNX1 and p53, 
respectively (Fig. 1f). These observations raise a possibility that AML cells lacking RUNX1 might survive due to 
the enhanced expression of CBFB. Given the positive correlation between the expression levels of p53 and CBFB 
in a variety of AML cases as shown in Fig. 1b, it is likely that RUNX1 depletion-mediated up-regulation of CBFB 
is under the control of the accumulated p53, and thus creating an autonomous RUNX1-p53-CBFB feedback loop 
regulatory system for AML cell proliferation (Fig. 1g).
Intriguingly, we have found out multiple p53-responsive element-like sequences within the putative CBFB 
promoter region (at positions from −2000 to +200 relative to the transcription start site (+1)) (Fig. 2a and 
b). Kenzelmann BD and Li M et al. have previously demonstrated that p53 bound to CBFB promoter region as 
examined by chromatin immunoprecipitation (ChIP) with anti-p53 antibody followed by DNA sequencing25,26. 
In accordance with these results, the indicated CBFB genomic fragments (P1, P2, P3, P4 and P5) containing 
the possible p53-responsive element-like DNA sequences were detectable in anti-p53 immunoprecipitates under 
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our experimental conditions (Fig. 2c). Additionally, Nutlin-3 treatment markedly stimulated CBFB transcrip-
tion (Fig. 2d). In luciferase reporter assay with CBFB promoter region (−1884 bp to +150 bp of transcriptional 
start site (TSS)), Nutlin-3 treatment indeed up-regulated the CBFB promoter activity (Supplementary Fig. S3a). 
Together, these data strongly suggest the vital role of p53 in the transcriptional regulation of CBFB.
Unidirectional compensatory regulatory loop of RUNX1-p53-CBFB. To further confirm the exist-
ence of RUNX1-p53-CBFB regulatory loop, we have conducted a series of gene knockdown and restore exper-
iments in AML cells. As shown in Fig. 3a, the additional knockdown of p53 in RUNX1-depleted MV4-11 cells 
Figure 1. p53 induces CBFB expression in AML cells. (a) RUNX1 depletion induces p53 and CBFB. MV4-11 
cells were lentivirally-transduced with control (sh_Luc) or with shRNAs targeting RUNX1 (sh_Rx1 #1 and 
sh_Rx1 #2) and treated with 3 μM doxycycline. Forty-eight hours after treatment, cell lysates were prepared 
and analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a loading control. 
(b) Correlation between p53 and CBFB expressions in AML patients from 2 independent clinical datasets 
(GSE22845; n = 154, GSE21261; n = 96). P value by Spearman’s correlation. (c) Knockdown of p53 promotes 
down-regulation of CBFB and RUNX1. MV4-11 cells were lentivirally-transduced with control (sh_Luc) or 
with shRNAs targeting p53 (sh_p53 #1 and sh_p53 #2) and treated as in (a). Cell lysates were analyzed by 
immunoblotting with the indicated antibodies. GAPDH was used as a loading control. (d) Nutlin-3 exposure 
induces CBFB. MV4-11 cells were treated with Nutlin-3 for 24 hours at the indicated concentrations. After the 
treatment, cell lysates were analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a 
loading control. (e) Depletion of CBFB causes down- and up-regulation of RUNX1 and p53, respectively. MV4-
11 cells lentivirally-transduced with control (sh_Luc.) or shRNAs targeting CBFB (sh_CBFB #1 and sh_CBFB 
#2) were treated as in (a). Forty-eight hours after the treatment, cell lysates were analyzed by immunoblotting 
with the indicated antibodies. GAPDH was used as a loading control. (f) Forced expression of CBFB increases 
and decreases RUNX1 and p53, respectively. MV4-11 cells were transduced with control lentivirus or with 
lentivirus encoding CBFB (CBFB O/E) and treated as in (a). Forty-eight hours after the treatment, cell lysates 
were analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a loading control. Signal 
intensities of p53 in each lane were measured by Image Lab software and shown in red. (g) Working model 
of our present study. RUNX1 depletion induces p53, which results in an increase in CBFB expression level. 
Intracellular CBFB accumulation stabilizes the residual RUNX1 to compete the RUNX1-inhibition therapy, thus 
creating the cell-autonomous feedback regulatory loop of RUNX1-p53-CBFB in AML cells.
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reduced the expression level of CBFB to the baseline level. Together with the results shown in Fig. 1a, these data 
imply that p53 induced by RUNX1 gene silencing subsequently promotes the expression of CBFB in AML cells. 
While, knockdown of p53 led to a significant suppression of CBFB as well as RUNX1, and the decreased expres-
sion level of RUNX1 was restored by overexpression of CBFB (Fig. 3b). These observations are suggestive that 
CBFB induced by p53 subsequently stabilizes RUNX1 in AML cells. Finally, we have examined the expression lev-
els of RUNX1 and p53 in CBFB-knocked down MV4-11 cells. As seen in Fig. 3c, CBFB gene silencing decreased 
and increased the expression levels of RUNX1 and p53, respectively. As expected, forced expression of RUNX1 
in CBFB-depleted MV4-11 cells caused a reduction in p53 to the control level. These results indicate that silenc-
ing of CBFB destabilizes RUNX1, which in turn induces p53 in AML cells. Consistent with these findings, the 
down-regulation of RUNX1 was detectable in MV4-11 cells at 6 hours after the treatment with Ro5-3335, which 
has been shown to facilitate the specific dissociation of RUNX1 from CBFB27 (Fig. 3d). Nine hours after Ro5-3335 
treatment, the amounts of p53 and CBFB were increased in a time-dependent manner. Collectively, these results 
strongly suggest the presence of unidirectional compensatory circuit of RUNX1-p53-CBFB in AML cells.
RUNX1-p53-CBFB axis confers resistance to anti-leukemia therapy. Although the majority of pri-
mary de novo AML cases harbor wild-type p53, a small number of AML patients do carry p53 mutations. Since 
over 90% of p53 mutations occur within its sequence-specific DNA-binding domain, it is indicative that mutated 
p53 has an ability to recognize and bind to DNA sequences distinct from those of wild-type p53. On the other 
hand, it has also been described in several reports that p53-target sequences remain unchanged regardless of 
p53 status8,9,11,13. According to our RUNX1-p53-CBFB loop working model, the stabilized mutant p53 possi-
bly augments this feedback regulatory loop through the direct transactivation of CBFB and potentially contrib-
utes to the acquired resistance to RUNX1-inhibition therapy (Fig. 4a). We thus examined whether p53 mutants 
could up-regulate CBFB expression. To this end, we have generated three expression plasmids of representative 
Figure 2. p53 directly transactivates CBFB expressions. (a) List of the putative p53-responsive elements 
within 5′-upstream region of CBFB. (b) Schematic drawing of 5′-upstream region of CBFB. The positions of 12 
canonical p53-responsive elements (R1-R12) and the primer sets (P1- P5) used for ChIP analysis are shown. 
(c) p53 binds to CBFB promoter region. MV4-11 cells were treated with 1 μM of Nutlin-3. Twenty-four hours 
after treatment, cells were cross-linked and immunoprecipitated with anti-p53 antibody, an isotope-matched 
control IgG or with anti-Histone H3 antibody. ChIP products were subjected to PCR-based amplification 
with the indicated primer sets (see Supplementary Table S2), and RPL30 as a negative control. (d) Nutlin-3 
treatment induces CBFB transcription. MV4-11 cells were exposed to 1 μM of Nutlin-3. Twenty-four hours post 
treatment, total RNA was prepared and analyzed by real-time RT-PCR. Values are normalized to that of DMSO 
treated cells (n = 3). Data are mean ± SEM. *P < 0.05, by two-tailed Student’s t-test.
www.nature.com/scientificreports/
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p53 mutants (R175H, R248W and R273C) and introduced them into HEK293T cells. As shown in Fig. 4b and 
c, like wild-type p53, these mutants significantly induced CBFB. In luciferase reporter assays using CBFB pro-
moter (Supplementary Fig. 4a), these mutants retained ability enough to transactivate CBFB expressions. As we 
have expected, ChIP assay with anti-p53 antibody in p53-mutated AML cell line MV4-11NR (R248W) revealed 
the binding of mutant p53 to the CBFB promoter region. In addition, wild-type p53 inducer CP-3139828 and 
RUNX1-CBFB inhibitor Ro5-3335 have synergistically worked (combination index (CI) < 1 at fraction of affected 
(Fa) = 0.5) in MV4-11NR cells bearing p53 mutation, which were originally resistant to Ro5-3335 treatment 
(Fig. 4d). Consistent with these findings, knockdown of mutant p53 in MV4-11NR cells significantly suppressed 
CBFB expression (Supplementary Fig. 4c). MDM2 inhibition with Nutlin-3 didn’t induce enough p53 elevation in 
MV4-11NR cells, probably due to the saturated expression of stablized mutant p53 in these cells (Supplementary 
Fig. 4d). These findings collectively indicated that even a mutated p53 can transactivate CBFB expressions.
We have previously reported a potent RUNX inhibitor Chb-M’ and its efficacy in AML cells5. Based on our 
previous results, Chb-M’ impaired the interaction of RUNX family members with their consensus binding 
sequences on the genome DNA, and then exerted its anti-leukemic effect (Fig. 4e). Consistent with our current 
findings, MV4-11 cells expressing an exogenous CBFB acquired the resistance to Chb-M’ (Fig. 4f). Therefore, 
these results indicate that p53 mutations possibly confer resistance to RUNX1-inhibition therapy through the 
induction of CBFB.
Figure 3. Unidirectional regulatory loop of RUNX1-p53-CBFB. (a) RUNX1-depletion-mediated up-regulation 
of CBFB is attenuated by the additional knockdown of p53 (left panel). MV4-11 cells were lentivirally-
transduced with the indicated combinations of shRNAs, and treated with 3 μM of doxycycline. Forty-eight 
hours after treatment, cell lysates were analyzed by immunoblotting with the indicated antibodies. GAPDH 
was used as a loading control (right panel). (b) p53-depletion-mediated decrease in the amount of RUNX1 
is restored by ectopic expression of CBFB (left panel). MV4-11 cells were transduced with the indicated 
combinations of lentivirus vectors and treated with 3 μM of doxycycline. Forty-eight hours after treatment, 
cell lysates were analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a loading 
control (right panel). (c) CBFB-depletion-mediated increase in the amount of p53 is attenuated by forced 
expression of RUNX1 (left panel). MV4-11 cells were transduced with the indicated combinations of lentivirus 
vectors and treated with 3 μM of doxycycline. Forty-eight hours after treatment, cell lysates were analyzed by 
immunoblotting with the indicated antibodies. GAPDH was used as a loading control (right panel). (d) The 
presence of unidirectional regulatory loop of RUNX1-p53-CBFB (upper panel). MV4-11 cells were exposed to 
2 μM of Ro5-3335. At the indicated time points after treatment, cell lysates were analyzed by immunoblotting 
with the indicated antibodies. GAPDH was used as a loading control (lower panel). Signal Intensities of the 
indicated bands were quantitated by Image Lab software.
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To further verify the relationship between p53 expression/mutation and resistance to RUNX1 inhibition, we 
have employed the unbiased methods. Firstly, we have cultured Chb-M’-naïve MV4-11 cells in the medium con-
taining a gradually increasing amounts of Chb-M’, and finally established the Chb-M’-resistant MV4-11 clones 
(MV4-11M’R) through the continuous selection of the resistant cells in vitro for up to 4 months (Fig. 5a and b). 
Intriguingly, the expression analyses demonstrated that MV4-11M’R cells expressed a larger amount of p53 
and CBFB than the parental MV4-11 cells (Fig. 5c), and their expression levels have increased in response to 
Chb-M’ in a dose-dependent manner (Fig. 5d). We then comprehensively examined the mutation frequency of 
p53 in MV4-11M’R cells by using the next generation sequencing (NGS) and demonstrated that the mutation 
frequency of p53 at codon R248W is around 45% (Fig. 5e), implying that one of 6 hot-spot mutations of p53 
(R248W) occurs in most of the Chb-M’-resistant MV4-11M’R cells. This mutated p53 (R248W) has indeed an 
ability to up-regulate CBFB expression as shown in Fig. 4b and c. We have also carried out the in vivo selection 
for Chb-M’-resistant clones (Fig. 5f) and found a marked induction of p53 and CBFB in Chb-M’-resistant AML 
cells (Fig. 5g). These observations strongly suggest that the RUNX inhibition-mediated treatment permits the 
selective proliferation of p53-mutated AML cells and these cells acquire the enhanced tumorigenicity through the 
potentiated p53-CBFB-RUNX feedback loop. Notably, CBFB-overexpression in MV4-11 cells conferred prolifer-
ative advantage and resistance to Ara-C (cytarabine), a widely-used first line clinical anti-leukemia drug (Fig. 6a, 
Supplementary Fig. 5a). Making a sharp contrast to CBFB overexpression, knockdown of CBFB in MV4-11 cells 
conferred significant sensitivity to Ara-C (Supplementary Fig. 5b and c). When all RUNX family expressions 
were knocked down in CBFB-overexpressed MV4-11 cells, CBFB-mediated Ara-C resistance was significantly 
reverted (Supplementary Fig. 5d and e), suggesting that CBFB-induced drug-resistance was probably mediated 
by stabilized RUNX family members.
We have also observed that Ara-C-resistant MV4-11 cells (MV4-11AR) express a significant larger amount of 
CBFB than Ara-C-naïve parental MV4-11 cells (Fig. 6b and c). In addition, Ara-C exposure further augmented 
CBFB expression in MV4-11AR cells (Fig. 6d). In a good agreement with these results, a larger amount of CBFB 
Figure 4. Mutated p53 induces CBFB. (a) Schematic abstract showing the different biological response to 
RUNX1 inhibition of p53-proficient and p53-mutated tumors. (b) p53 mutants induce the expression of CBFB. 
HEK293T cells were transfected with the indicated expression plasmids. Forty-eight hours after transfection, 
cell lysates were analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a loading 
control. (c) Cumulative results of (a). Signal intensities of the bands for CBFB were measured by Image Lab 
software and adjusted to those of GAPDH bands. Values were normalized to that of control samples (n = 3). 
(d) Combination index plots of Ro5-3335 and CP-31398 in p53-mutated (MV4-11NR) AML cells (n = 3). (e) 
Schematic illustration showing the interaction site of Chb-M’ in the RUNX1-p53-CBFB loop. Chb-M’ binds 
to RUNX1-consensus binding sequences on the genome DNA, inhibits the recruitment of RUNX1 onto its 
target sites, and thereby activating p53 pathway. (f) IC50 values of Chb-M’ in MV4-11 cells transduced with 
the empty lentivirus or with the lentivirus for CBFB (CBFB O/E). Cells were simultaneously treated with 3 μM 
of doxycycline and various concentrations of Chb-M’ for 48 hours (n = 3). Data are mean ± SEM. *P < 0.05, 
**P < 0.01, by two-tailed Student’s t-test.
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was detectable in patients’ AML samples obtained at their relapse phase than those obtained at the primary phase 
(Fig. 6e). Extensive analysis of the clinical datasets29 revealed that the overexpression of CBFB confers an accel-
erated disease progression and shortened overall survival periods not only to AML patients but also to various 
types of cancers (Fig. 6f and Supplementary Fig. S6). Taken together, our present results strongly suggest that the 
p53-CBFB-RUNX feedback loop is tightly engaged in the tumorigenesis as well as the acquisition of the serious 
resistance to chemotherapy including the RUNX-specific inhibition therapy.
Discussion
The context-dependent oncogenic and oncosuppressive functions of RUNX family members (RUNX1, RUNX2 
and RUNX3) have been well-described in multiple studies1. A growing body of recent evidence supports the 
notion that RUNX family is tightly linked to the development and maintenance of AML as well as various types of 
cancers3,5,30,31. On the other hand, the functional significance of their heterodimeric partner, CBFB, in oncogen-
esis has relatively little been known so far. Recently, we have found the redundant functions of RUNX1, RUNX2 
and RUNX3 in tumorigenesis and demonstrated that shRNA-mediated knockdown of RUNX1 in AML cells 
reciprocally up-regulates RUNX2 and RUNX3 expressions5. From these experiments, we have also found RUNX1 
Figure 5. Mutated p53-dependent induction of CBFB contributes to the resistance to RUNX1 inhibition 
therapy. (a) Schematic diagram of the procedure to establish Chb-M’-resistant MV4-11 clones (MV4-11M’R) 
and subsequent mutation analysis by next generation sequencing (NGS). (b) Calculation of IC50 of Chb-M’ 
in Chb-M’-naïve and Chb-M’-resistant MV4-11 cells (MV4-11M’R) (n = 3). (c) Induction of p53 and CBFB 
in MV4-11 M’R cells. Cell lysates prepared from the parental MV4-11 and MV4-11M’R cells were analyzed by 
immunoblotting with the indicated antibodies. GAPDH was used as a loading control. (d) Chb-M’ treatment 
further stimulates the expression levels of p53 and CBFB in MV4-11M’R cells. MV4-11M’R cells were exposed 
to the indicated concentrations of Chb-M’. Twenty-four hours after treatment, cell lysates were prepared 
and subjected to immunoblotting with the indicated antibodies. GAPDH was used as a loading control. (e) 
Frequent p53 mutation at codon R248W in MV4-11 M’R cells. Genomic DNA was prepared from MV4-11 M’R 
cells according to the standard procedure, and analyzed for p53 mutations by next generation sequencing. (f) 
Schematic drawing of the transplantation assay in NOG mice. Chb-M’ treatment (twice/week) was continued 
until the recipient mice show the sign of leukemia development. AML cells were then extracted from sacrificed 
mice with leukemia. (g) Chb-M’-resistant AML cells highly express p53 and CBFB. Cell lysates prepared from 
parental, control and resistant cells were analyzed by immunoblotting with the indicated antibodies. GAPDH 
was used as a loading control.
www.nature.com/scientificreports/
8ScIeNtIfIc REPORts | 7: 16604  | DOI:10.1038/s41598-017-16799-z
depletion-mediated induction of CBFB. Moreover, the additional knockdown of RUNX family genes augmented 
RUNX1 silencing-induced expression of CBFB and p53, which prompted us to investigate the possible interac-
tions of CBFB with p53. Previously, it has been shown that CBFB stabilizes the RUNX transcription complex and 
enhances its DNA-binding capability6,22,23. Since the results obtained from our series of gene knockdown and 
overexpression experiments did not support the above-mentioned hypothesis, it is likely that there exists an alter-
native molecular mechanism behind the regulation of CBFB expression in AML cells. Although we have found 
for the first time that CBFB transcription is modulated by RUNX family members, we have failed to find out any 
consensus RUNX-binding sequences (5′-TGTGGT-3′ or 5′-TGCGGT-3′) within the proximal promoter region 
of CBFB. Besides, previously-reported ChIP-sequencing (ChIP-seq) assays with anti-RUNX1 antibody showed 
no significant peaks in the regulatory region of CBFB (GSE22178 and GSE31221)5,32,33. Therefore, it is unlikely 
that CBFB is directly transactivated by RUNX family members. On the other hand, ChIP-seq assays with anti-p53 
antibody repeatedly proved p53 bindings to CBFB regulatory region (GSE46240 and GSE26361), which results 
are consistent with our findings as we have mentioned in the Results section25,26. Together with the present results 
showing that p53 directly transactivates CBFB promoter through its p53-responsive element-like sequences, it is 
conceivable that RUNX1 regulates the expression of CBFB not directly but indirectly via p53.
In addition to the transcriptional regulatory mechanism of CBFB, we have also demonstrated that 
RUNX1-p53-CBFB regulatory circuit contributes to the acquisition of treatment resistance of AML cells. 
Collectively, our present study identified the novel molecular mechanism behind CBFB regulation and its indis-
pensable roles in tumorigenesis, which provides an insight into understanding how AML cells could become 
resistant to RUNX1-inhibition therapy (Fig. 7).
In conclusion, our present study strongly suggests that an autonomous RUNX1-p53-CBFB regulatory triangle 
plays a vital role in the maintenance and the acquisition of chemo-resistance of AML cells, and potentially pro-
vides novel therapeutic targets for anti-leukemia strategy.
Figure 6. Ectopic expression of CBFB confers resistance to the conventional anti-leukemia therapies. (a) 
IC50 values of Ara-C in CBFB-overexpressed MV4-11 cells. MV4-11 cells were transduced with lentivirus 
expressing CBFB (CBFB O/E) or control empty lentivirus. Cells were then treated simultaneously with 
3 μM doxycycline and various concentrations of Ara-C. Forty-eight hours after treatment, IC50 values were 
calculated (n = 3). **P < 0.01, by two-tailed Student’s t-test. (b) IC50 values of Ara-C in Ara-C-naïve MV4-
11 cells and Ara-C-resistant MV4-11 cells (MV4-11AR) (n = 3). (c) MV4-11AR cells highly express p53 and 
CBFB. Cell lysates prepared from parental MV4-11 cells and Ara-C-resistant MV4-11AR cells were analyzed 
by immunoblotting with the indicated antibodies. GAPDH was used as a loading control. (d) Ara-C treatment 
further augments p53 and CBFB expressions in MV4-11AR cells. MV4-11AR cells were treated with DMSO or 
with the increasing concentrations of Ara-C. Twenty-four hours after treatment, cell lysates were prepared and 
analyzed by immunoblotting with the indicated antibodies. GAPDH was used as a loading control. (e) A higher 
expression level of CBFB in AML cells obtained from the patients at the relapse phases relative to that at the 
primary phases (GSE17855 and GSE52891, n = 23). (f) Overall survival of AML patients with a higher or with 
a lower expression level of CBFB (GSE12417, high n = 17, low n = 62). P value by log-rank (Mantel-Cox) test. 
Data are mean ± SEM.
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Materials and Methods
Cell lines. AML-derived MOLM13 and MV4-11cells were purchased from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (DSMZ), Germany and American Type Culture Collection (ATCC), 
USA, respectively. AML-derived MV4-11NR cells harboring TP53 R248W mutation were kind gift from Dr. T. 
Ikezoe (Department of Hematology and Respiratory Medicine, Kochi University, Kochi, Japan). Embryonic kid-
ney HEK293T cells were provided from Japanese Collection of Research Bioresources (JCRB), Japan. HEK293T 
cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (PS) in incubators with humidified atmospheres of 5% 
CO2 and 95% air at 37 °C. The other cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 
containing 10% FBS and 1% PS under 5% CO2 and 95% air at 37 °C.
IC50 evaluation. For cell survival assay, cells were seeded at a density of 1 × 105 cells/mL. The indicated con-
centrations of PI polyamides or drugs were added to the culture medium and cells were incubated for 48 hours. 
Cell viability was then assessed by WST assay using Cell Count Reagent SF (nacalai tesque, Inc.) and Infinite® 200 
PRO multimode reader (TECAN) according to the manufacturer’s instructions. Percent inhibition curves were 
drawn and IC50 of the indicated compounds was calculated based on the median-effect method34.
Real-time quantitative PCR (qRT-PCR). Total RNA was isolated by using RNeasy mini kit (Qiagen) and 
reverse-transcribed with Reverse script kit (TOYOBO) to generate cDNA. Real-time quantitative polymerase 
chain reaction (PCR) was carried out with 7500 Real-Time PCR System (Applied Biosystems) according to the 
manufacturer’s recommendations. The results were normalized to GAPDH levels. Relative expression levels were 
calculated using the 2-ΔΔCt method. Primers used for qRT-PCR were listed in Supplementary Table S1.
ChIP-qPCR. Chromatin immunoprecipitation assay (ChIP) was performed using SimpleChIP® Plus 
Enzymatic Chromatin IP Kit (Cell Signaling Technology, USA) according to the manufacturer’s protocols. In 
brief, cells were cross-linked in 1% formaldehyde in PBS for 10 min at room temperature. After glycine quench-
ing, cell pellets were collected, lysed and then subjected to sonication with Q55 sonicator system (QSONICA, 
USA). The supernatant was diluted with the same sonication buffer and processed for immunoprecipitation 
with the following antibodies at 4 °C overnight. Anti-p53 antibody (1C12, #2524, Cell Signaling Technology). 
The agarose beads were washed, chromatin DNA was reverse cross-linked and purified by ethanol precipitation. 
Figure 7. Auto-regulatory feedback loop of RUNX1-p53-CBFB. RUNX1-inhibition treatment induces p53. 
Induced p53 directly binds to CBFB promoter and stimulates its transcription and translation, which in turn 
acts as a platform for the stabilization of RUNX1, thereby creating the compensative RUNX1-p53-CBFB 
feedback loop.
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Following ChIP, precipitated DNA was quantified by qPCR using the standard procedures for 7500 Real-Time 
PCR System (Applied Biosystems). Primers used for ChIP-qPCR were listed in Supplementary Table S2.
siRNA interference. Specific shRNAs targeting human RUNX1, RUNX2, RUNX3, CBFB and TP53 were 
designed and sub-cloned into pENTR4-H1tetOx1, CS-RfA-ETBsd, CS-RfA-ETV and CS-RfA-ETR vectors 
(RIKEN BRC). Non-targeting control shRNA was designed against luciferase (sh_Luc). The target sequences 
were provided in Supplementary Table S3.
Expression plasmids. Human RUNX1, CBFB and p53 cDNAs were amplified by PCR and then inserted into 
CSII-EF-MCS-IRES2-Venus, CSII-EF-MCS-IRES2-hKO1 and CSIV-TRE-Ubc-KT expression vectors. Series of 
p53 point mutations (R248W, R175H and R273C) were created by KOD -Plus- Mutagenesis Kit (TOYOBO Co, 
Ltd.). All of the PCR products were verified by DNA sequencing.
Production and transduction of lentivirus. For the production of lentivirus, HEK293T cells were 
transiently co-transfected with lentivirus vectors such as psPAX2 and pMD2.G by polyethylenimine (PEI, 
Sigma-Aldrich). Forty-eight hours after transfection, viral supernatants were collected and immediately used for 
infection, and then successfully transduced cells were sorted by flow cytometer Aria III (BD Biosciences) based 
on the immunofluorescence (Kusabira-Orange or Venus).
Immunoblotting. Immunoblotting was conducted as described previously35. Membranes were probed with 
the following primary antibodies: anti-RUNX1 (A-2, Santa Cruz Biotechnology, Inc.), anti-GAPDH (FL-335, 
Santa Cruz Biotechnology, Inc.), anti-RUNX2 (D1L7F, Cell Signaling Technology), anti-RUNX3 (D6E2, Cell 
Signaling Technology), anti-CBFB (FL-182, Santa Cruz Biotechnology, Inc.) and anti-p53 (1C12, Cell Signaling 
Technology) antibodies. HRP-conjugated anti-rabbit IgG and anti-mosue IgG (Cell Signaling Technology) were 
used as the secondary antibodies. Blots were visualized using Chemi-Lumi One Super (nacalai tesque, Inc.) and 
ChemiDocTM XRS + Imager (Bio-Rad Laboratories, Inc.) according to the manufacturers’ recommendations. 
Protein levels were quantified with Image Lab Software (Bio-Rad Laboratories, Inc.).
Next generation sequencing. Deep sequencing of target exons of TP53 was performed as described pre-
viously with slight modifications36. Briefly, tumor DNA specimens prepared from Chb-M’-naïve and -resistant 
MV4-11 cells were analyzed for possible mutations in TP53. After the extraction of genomic DNA using DNeasy 
Blood & Tissue Kit (QIAGEN), its concentration was measured using the PicoGreen® reagents (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. Next, the entire coding sequences of TP53 gene were 
amplified by independent genomic PCR with a NotI linker attached primer (See Supplementary Table S4 for 
specific PCR primers). After checking the successful amplification by agarose gel electrophoresis, the PCR 
products from each sample were combined together, followed by purification of DNA using FastGene Gel/PCR 
Extraction Kit (Nippon Genetics) and digestion with NotI. The digested DNA was purified again and an aliquot 
of 2.5 μg of purified DNA was ligated with T4 DNA ligase for 5 hours, sonicated into ~200 bp in length on average 
using Covaris®, and used for generation of sequencing libraries using NEBNext Ultra DNA Library Prep Kit for 
Illumina (New England Biolabs). The libraries were then subjected to deep sequencing on Illumina Miseq® fol-
lowing the standard protocol.
Luciferase reporter assay. Putative promoter region of CBFB (−1884 bp to +150 bp of TSS) was cloned 
from the genomic DNA of MV4-11 cells using the following primers; F 5′-CCTTGAGGCTGACAATGAGAG -3′ 
and R 5′-CCGCTTCCCTTTGTTTCAG -3′, and then subcloned into pGL4.20 [luc2/Puro] vector (Promega). 
Both pGL4.20 CBFB promoter vector and pRL-CMV control vector (TOYO B-Net Co., LTD.) were co-transfected 
into HEK293T cells. Promoter activities were measured using PicaGene Dual Sea Pansy Luminescence Kit 
(TOYO B-Net Co., LTD.) and detected by ARVO × 5 (Perkin Elmer) according to the manufacturer’s instructions.
Statistics. Statistical significance of differences between control and experimental groups was assessed by 
a 2-tailed unpaired Student’s t test, and declared if the p value was less than 0.05. Equality of variances in two 
populations was calculated with F-test. The results were represented as the average ±SEM values obtained from 
three independent experiments. In transplantation experiments, animals were randomly allocated to each exper-
imental group and the treatments were given with blinding. To examine the overall survival of cancer patients, 
PrognoScan software was utilized for data extraction and calculation of minimal p value29. Survival between the 
indicated groups was compared using the log-rank test. For the measurement of correlation between mRNA or 
protein expressions, Spearman’s rank correlation coefficient was used.
Mice. NOD/Shi-scid, IL-2RγKO (NOG) mice were purchased from Central Institute for Experimental 
Animals, Japan. Littermates were used as controls in all experiments.
Xenograft mice model. Xenograft mice models of human cancer cell lines were developed using NOG 
mice. For leukemia mice models, 2.5 × 106 cells/body of MV4-11 cells were intravenously injected. Peripheral 
blood (PB) was then collected every week and chimerism was checked by flow cytometer using anti-human CD45 
antibody (BD Biosciences). One week after injection, mice were treated with PI polyamides (320 μg/kg body 
weight, twice a week IV injections) or with the equivalent amount of dimethyl sulfoxide (DMSO).
Synthesis of PI polyamides. Synthesis of Chb-M’ was conducted as previously reported5. Briefly, 
Py-Im polyamide supported by oxime resin was prepared in a stepwise reaction by Fmoc solid-phase proto-
col. The product with oxime resin was cleaved with N,N-dimethyl-1,3-propane diamine (1.0 mL) at 45 °C for 
3 h. The residue was dissolved in the minimum amount of dichloromethane and washed with diethyl ether to 
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yield a 59.6 mg. To the crude compound (59.6 mg, 48.1 μmol), a solution of chlorambucil (32.6 mg, 107 μmol), 
PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate) (101 mg, 195 μmol), and 
N,N-diisopropylethylamine (100 μL, 581 μmol) in N,N-dimethylformamide (DMF) (300 μL) was added. The 
reaction mixture was incubated for 1.5 h at room temperature, washed with diethyl ether and DMF for three 
times, and dried in vacuo. The crude product was purified by reversed-phase flash column chromatography 
(water with 0.1% trifluoroacetic acid/MeCN). After lyophilization, product was obtained (30.2 mg, 19.8 μmol). 
Machine-assisted polyamide syntheses were performed on a PSSM-8 (Shimadzu) system with computer-assisted 
operation. Flash column purifications were performed by a CombiFlash Rf (Teledyne Isco, Inc.) with C18 RediSep 
Rf Flash Column. Electrospray ionization time-of-flight mass spectrometry (ESI-TOF MS) was performed on a 
Bio-TOF II (Bruker Daltonics) mass spectrometer by using positive ionization mode and proton nuclear mag-
netic resonance (1H NMR) spectra were recorded with a JEOL JNM ECA-600 spectrometer operating at 600 MHz 
and in parts per million (ppm) downfield relative to tetramethylsilane used as an internal standard to verify the 
quality of synthesized PI polyamides.
Study approval. All animal studies were properly conducted in accordance with the Regulation on 
Animal Experimentation at Kyoto University based on International Guiding Principles for Biomedical 
Research Involving Animals. All procedures employed in this study were approved by Kyoto University Animal 
Experimentation Committee (Permit Number: Med Kyo 14332).
References
 1. Ito, Y., Bae, S. C. & Chuang, L. S. The RUNX family: developmental regulators in cancer. Nat Rev Cancer 15, 81–95, https://doi.
org/10.1038/nrc3877 (2015).
 2. Levanon, D. & Groner, Y. Structure and regulated expression of mammalian RUNX genes. Oncogene 23, 4211–4219, https://doi.
org/10.1038/sj.onc.1207670 (2004).
 3. Goyama, S. et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest 123, 3876–3888, 
https://doi.org/10.1172/JCI68557 (2013).
 4. Klunker, S. et al. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible 
regulatory T cells. J Exp Med 206, 2701–2715, https://doi.org/10.1084/jem.20090596 (2009).
 5. Morita, K. et al. Genetic regulation of the RUNX transcription factor family has antitumor effects. J Clin Invest 127, 2815–2828, 
https://doi.org/10.1172/JCI91788 (2017).
 6. Berardi, M. J. et al. The Ig fold of the core binding factor alpha Runt domain is a member of a family of structurally and functionally 
related Ig-fold DNA-binding domains. Structure 7, 1247–1256 (1999).
 7. Bieging, K. T., Mello, S. S. & Attardi, L. D. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14, 
359–370, https://doi.org/10.1038/nrc3711 (2014).
 8. el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. & Vogelstein, B. Definition of a consensus binding site for p53. Nat Genet 
1, 45–49, https://doi.org/10.1038/ng0492-45 (1992).
 9. Wei, C. L. et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207–219, https://doi.
org/10.1016/j.cell.2005.10.043 (2006).
 10. Wilhelm, M. T., Mendez-Vidal, C. & Wiman, K. G. Identification of functional p53-binding motifs in the mouse wig-1 promoter. 
FEBS Lett 524, 69–72 (2002).
 11. Degtyareva, N., Subramanian, D. & Griffith, J. D. Analysis of the binding of p53 to DNAs containing mismatched and bulged bases. 
J Biol Chem 276, 8778–8784, https://doi.org/10.1074/jbc.M006795200 (2001).
 12. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat Cell Biol 15, 2–8, https://doi.org/10.1038/ncb2641 (2013).
 13. Freed-Pastor, W. A. & Prives, C. Mutantp53: one name, many proteins. Genes Dev 26, 1268–1286, https://doi.org/10.1101/
gad.190678.112 (2012).
 14. Ashcroft, M. & Vousden, K. H. Regulation of p53 stability. Oncogene 18, 7637–7643, https://doi.org/10.1038/sj.onc.1203012 (1999).
 15. Frum, R. A. & Grossman, S. R. Mechanisms of mutant p53 stabilization in cancer. Subcell Biochem 85, 187–197, https://doi.
org/10.1007/978-94-017-9211-0_10 (2014).
 16. Peller, S. & Rotter, V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 21, 
277–284, https://doi.org/10.1002/humu.10190 (2003).
 17. Bowen, D. et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated 
with very poor prognosis. Leukemia 23, 203–206, https://doi.org/10.1038/leu.2008.173 (2009).
 18. Rucker, F. G. et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number 
alterations, monosomal karyotype, and dismal outcome. Blood 119, 2114–2121, https://doi.org/10.1182/blood-2011-08-375758 
(2012).
 19. Pedersen-Bjergaard, J., Christiansen, D. H., Desta, F. & Andersen, M. K. Alternative genetic pathways and cooperating genetic 
abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 20, 1943–1949, https://
doi.org/10.1038/sj.leu.2404381 (2006).
 20. Wong, T. N. et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518, 
552–555, https://doi.org/10.1038/nature13968 (2015).
 21. Harutyunyan, A., Klampfl, T., Cazzola, M. & Kralovics, R. p53 lesions in leukemic transformation. N Engl J Med 364, 488–490, 
https://doi.org/10.1056/NEJMc1012718 (2011).
 22. Warren, A. J., Bravo, J., Williams, R. L. & Rabbitts, T. H. Structural basis for the heterodimeric interaction between the acute 
leukaemia-associated transcription factors AML1 and CBFbeta. EMBO J 19, 3004–3015, https://doi.org/10.1093/emboj/19.12.3004 
(2000).
 23. Yan, J., Liu, Y., Lukasik, S. M., Speck, N. A. & Bushweller, J. H. CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic 
conformational equilibrium. Nat Struct Mol Biol 11, 901–906, https://doi.org/10.1038/nsmb819 (2004).
 24. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848, https://doi.
org/10.1126/science.1092472 (2004).
 25. Kenzelmann Broz, D. et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 
responses. Genes Dev 27, 1016–1031, https://doi.org/10.1101/gad.212282.112 (2013).
 26. Li, M. et al. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in 
embryonic stem cells. Mol Cell 46, 30–42, https://doi.org/10.1016/j.molcel.2012.01.020 (2012).
 27. Cunningham, L. et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high 
throughput screen against RUNX1-CBFbeta interaction. Proc Natl Acad Sci USA 109, 14592–14597, https://doi.org/10.1073/
pnas.1200037109 (2012).
 28. Foster, B. A., Coffey, H. A., Morin, M. J. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 
286, 2507–2510 (1999).
www.nature.com/scientificreports/
1 2ScIeNtIfIc REPORts | 7: 16604  | DOI:10.1038/s41598-017-16799-z
 29. Mizuno, H., Kitada, K., Nakai, K. & Sarai, A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC 
Med Genomics 2, 18, https://doi.org/10.1186/1755-8794-2-18 (2009).
 30. Ben-Ami, O. et al. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep 4, 1131–1143, https://doi.
org/10.1016/j.celrep.2013.08.020 (2013).
 31. Hyde, R. K., Zhao, L., Alemu, L. & Liu, P. P. Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 
knock-in mice. Leukemia 29, 1771–1778, https://doi.org/10.1038/leu.2015.58 (2015).
 32. Knezevic, K. et al. A Runx1-Smad6 rheostat controls Runx1 activity during embryonic hematopoiesis. Mol Cell Biol 31, 2817–2826, 
https://doi.org/10.1128/MCB.01305-10 (2011).
 33. Wu, J. Q. et al. Tcf7 is an important regulator of the switch of self-renewal and differentiation in a multipotential hematopoietic cell 
line. PLoS Genet 8, e1002565, https://doi.org/10.1371/journal.pgen.1002565 (2012).
 34. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme 
inhibitors. Adv Enzyme Regul 22, 27–55 (1984).
 35. Morita, K. et al. BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4. Leukemia 29, 2248–2256, 
https://doi.org/10.1038/leu.2015.137 (2015).
 36. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69, https://doi.org/10.1038/
nature10496 (2011).
Acknowledgements
This work was supported by Grant-in-Aid for Scientific Research (KAKENHI), We thank Dr. H. Miyoshi (RIKEN, 
BRC) for kindly providing lentivirus vectors encoding CSII-EF-MCS-IRES2-Venus, CSII-EF-MCS-IRES2-hKO1 
and CSIV-TRE-Ubc-KT.
Author Contributions
K.M. designed research, performed experiments, analyzed data and wrote the manuscript. M.N. performed 
experiments and analyzed data. C.T., S.M., H.K., K.Y. and H.M. helped to collect data. G.K., J.T, T.B., T.O., 
S.O., P.L., T.N. and S.A. participated in discussions and interpretation of the data and results and commented 
on research direction. H.S. designed and synthesized polyamides. Y.K. initiated the study, designed, supervised 
research and gave the final approval for submission.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-16799-z.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
